Skip to main content
Equibles

CANF · Can-Fite BioPharma Ltd.

Track CANF — free

Use CANF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CANF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.89 +0.00 (+0.00%) At close · Oct 20
Rebalance outlook locked
Market Cap
$5.73M
Shares
3.03M
Volume · Oct 20 18.6K Avg daily vol (3M) 358.64K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.89 Open$1.86 Day$1.82–1.92 52W close$1.76–10.40 Avg vol 30d46K Short int56K · 1.8% float · 1.2d Short vol31% DataJan 2020–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$405,000
Trailing 12 months
Net income (TTM)
−$9.55M
Trailing 12 months
Revenue growth YoY
-39.9%
Year over year
Operating margin
-2,403.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-166.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+127.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.8%
Latest settlement · 1.2 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −43%
below
Price vs 50-day avg −25%
below
RSI (14) 33
neutral
MACD trend Positive
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −15%
trailing
6-month return −37%
trailing
YTD return −53%
this year
Relative strength −45%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Accumulating
3 of 8 funds reported for Sep 30 · net +6.7K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.83% of float · ▼ -6.3% MoM · 1.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
8 holders — near 3-yr low, contrarian setup
Squeeze score 39
low risk · 0–100
Fundamentals
Weak
Revenue growth −40%
Y/Y
EPS growth +45%
Y/Y
Free cash flow $-9.0M
Quant / Vol
risk profile
Very High
Volatility 104%
annualized · 1-yr
Max drawdown −83%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−43% Bearish
Price vs 50-day avg
−25% Bearish
RSI (14)
33 Neutral
MACD trend
Positive Bullish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Accumulating
3 of 8 funds reported for Sep 30 · net +6.7K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.83% of float · ▼ -6.3% MoM · 1.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
8 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $2 Now $2 · 2% Range high $10
vs 200-day avg -43% vs 50-day avg -25%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CANF
Can-Fite BioPharma Ltd.
this stock
$5.73M — -39.9% — 1.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $96.65B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
9
% held
1.9%
Reported
3 of 8
Top holder
CITADEL ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Falling
Shares short
55.6K
Days to cover
1.2d
Change
-3.8K sh
View
Short Volume
Short vol %
31%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
4.3K
Value
$9.5K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
60.8%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$405.0K
Net income (FY)
$-9.8M
EPS diluted
$-5.97
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 9, 2026
This year
36
View
Exempt Offerings
Offering
$8.3M
Filed
Sep 10, 2026
View

Performance

5D 20D 120D MTD YTD
CANF -3.1% -15.3% -36.8% -14.1% -52.8%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -1.9% -14.7% -44.9% -14.9% -65.5%
Key facts CIK 1536196 CUSIP 13471N409 13F (30d) 3 filings 3 filers Visit website Investor relations